Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Landmark Bio will perform GMP manufacturing of clinical trial batches of Galapagos' development programs of chimeric antigen receptor (CAR) T-cell therapies in hematology-oncology in the Boston metropolitan area.
Lead Product(s): CAR T-cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Galapagos
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 06, 2023